Crossmark

Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)

Crossref DOI link: https://doi.org/10.1186/s13046-025-03434-3

Published Online: 2025-06-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pasello, Giulia

Pigato, Giulia

Scattolin, Daniela

Lando, Stefania

Potente, Sara

Romualdi, Chiara

Roma, Anna

Resi, Maria Vittoria

Frega, Stefano

Ferro, Alessandra

Maso, Alessandro Dal

Bonanno, Laura

Guarneri, Valentina

Lazzarini, Elisabetta

Indraccolo, Stefano
Funding

Funding for this research was provided by:

Università degli Studi di Padova
License Information

Text and Data Mining valid from 2025-06-19

Version of Record valid from 2025-06-19
More Information

Article History

Received: 12 March 2025

Accepted: 1 June 2025

First Online: 19 June 2025

Declarations

:

: This study has been approved by Istituto Oncologico Veneto Ethical Committee (Cod. Int CESC IOV: 2021-85). All patients signed an informed consent form before enrollment.

: All patient information has been anonymised and consent for publication of the current study was not required. All co-authors agreed for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below